Literature DB >> 2001340

Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary.

N G Davidson1, S Khanna, P H Kirwan, D Bircumshaw.   

Abstract

A total of 55 patients with epithelial ovarian carcinoma treated with platinum-based chemotherapy were followed for a minimum period of 2 years. Of these 22 patients had a prechemotherapy serum CA125 level of less than 50 ku/l and 33 patients had a serum CA125 level of greater than or equal to 50 ku/l. The 5-year actuarial survival of the two groups were 75% and 10% respectively. Prechemotherapy CA125 level taken 4 weeks after debulking surgery may predict the eventual survival outcome in epithelial ovarian cancer patients who undergo chemotherapy treatment.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2001340     DOI： 10.1016/s0936-6555(05)81038-6

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


  7 in total

1.  Prognostic value of parameters derived from white blood cell and differential counts in patients receiving palliative radiotherapy.

Authors:  Tetsuo Saito; Ryo Toya; Tomohiko Matsuyama; Akiko Semba; Keiya Matsuyama; Natsuo Oya
Journal:  Mol Clin Oncol       Date:  2016-07-22

2.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

3.  CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer.

Authors:  Elizabeth Won; Arti Hurria; Tao Feng; Supriya Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; William P Tew
Journal:  Int J Gynecol Cancer       Date:  2013-07       Impact factor: 3.437

4.  Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Ana Babic; Daniel W Cramer; Linda E Kelemen; Martin Köbel; Helen Steed; Penelope M Webb; Sharon E Johnatty; Anna deFazio; Diether Lambrechts; Marc T Goodman; Florian Heitz; Keitaro Matsuo; Satoyo Hosono; Beth Y Karlan; Allan Jensen; Susanne K Kjær; Ellen L Goode; Tanja Pejovic; Melissa Moffitt; Estrid Høgdall; Claus Høgdall; Iain McNeish; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2017-01-03       Impact factor: 2.506

5.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

6.  Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.

Authors:  Stephen Shuford; Christine Wilhelm; Melissa Rayner; Ashley Elrod; Melissa Millard; Christina Mattingly; Alina Lotstein; Ashley M Smith; Qi Jin Guo; Lauren O'Donnell; Jeffrey Elder; Larry Puls; S John Weroha; Xiaonan Hou; Valentina Zanfagnin; Alpa Nick; Michael P Stany; G Larry Maxwell; Thomas Conrads; Anil K Sood; David Orr; Lillia M Holmes; Matthew Gevaert; Howland E Crosswell; Teresa M DesRochers
Journal:  Sci Rep       Date:  2019-08-01       Impact factor: 4.379

7.  Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.

Authors:  Szymon Piatek; Grzegorz Panek; Zbigniew Lewandowski; Mariusz Bidzinski; Dominika Piatek; Przemyslaw Kosinski; Miroslaw Wielgos
Journal:  J Ovarian Res       Date:  2020-09-02       Impact factor: 4.234
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.